StockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research note issued to investors on Sunday morning. The brokerage issued a sell rating on the stock.

Ayala Pharmaceuticals Stock Performance

NASDAQ ADXS opened at $0.03 on Friday. The stock has a fifty day moving average of $0.04 and a 200-day moving average of $0.06. The stock has a market capitalization of $1.15 million, a P/E ratio of 0.00 and a beta of 1.62. Ayala Pharmaceuticals has a 52 week low of $0.00 and a 52 week high of $1.49.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.